Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
- Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure - Sales and marketing efforts to...
News
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
GAITHERSBURG, Md., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it entered into a...
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome
—Potential best-in-class targeted treatment for Netherton syndrome is company’s first protein therapeutic to advance to the clinic— —Initial data from...
Blue Point Brewing Hosts 20th Annual Cask Ales Festival
Sample More Than 150 Unique Firkin-Style Beers at Long Island’s Most Iconic Beer FestivalPATCHOGUE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE)...
BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
Strategic head-to-head study of BR-AC vs. standard of care aims to demonstrate healing superiority potential to support increased payor coverage...
Emergex T Cell-Priming Vaccine Candidate for Betacoronaviruses selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
NIAID will be conducting and sponsoring clinical trials to accelerate and to streamline the rapid development of next-generation COVID-19 vaccinesABINGDON,...
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
MALVERN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
Two informational posters for ORIGIN Phase 3 and ORIGIN Extend trials of atacicept in IgAN accepted for presentation at Kidney...
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
PIONEER study expands the investigation of atacicept into a broad definition of IgA nephropathy and into multiple autoimmune glomerular diseases,...
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
Glioblastoma study achieves milestone with successful dose escalation, setting stage for Phase 2MILAN and NEW YORK, Oct. 02, 2024 (GLOBE...
The Ensign Group Acquires Healthcare Campus in Nebraska
SAN JUAN CAPISTRANO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group...
Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer
ZUG, Switzerland, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mr. Char brings extensive experience in leading legal, compliance and corporate governance...
Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer
Mr. Char brings extensive experience in leading legal, compliance and corporate governance functions in successful biotech and medical device companiesThe...
Nexstim Receives NBS System 5 Order from European Customer
Press release, Helsinki, 2 October 2024 at 9 AM (EEST) Nexstim Receives NBS System 5 Order from European Customer Nexstim...
EssilorLuxottica Completes Acquisition of Supreme® from VF Corporation
EssilorLuxottica Completes Acquisition of Supreme® from VF Corporation Paris, France and Denver, Colorado (USA) (October 2, 2024 – 7am CEST)...
EssilorLuxottica Completes Acquisition of a Majority Stake in Heidelberg Engineering
EssilorLuxottica Completes Acquisitionof a Majority Stake in Heidelberg Engineering Paris, France and Heidelberg, Germany (October 2, 2024 – 7am CEST) –...
CARBIOS announces half-year 2024 financial results and presents its industrial and commercial progress
Construction progress of world’s first PET enzymatic biorecycling plant in France: in line with production targets in 2026Commercial development:...
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORLANDO, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority...
COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director
TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a...
Vision Sensing Acquisition Corp. Announces Intention to Extend the Period to Consummate Its Initial Business Combination to November 3, 2024
NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special...